Member Info for Howzaty

Was 22nd April last year so prepare for the wait!

Regarding Herd Immunity, there is no such thing in relation to Covid if we are to believe what the scientists have advised previously. Catch it and catch it again, combined with ones brain apparently shrinking a little with each infection absolutely b****y marvellous!

Not sure director buying would be possible given the AVA6000 information they are undoubtedly aware of. But hey ho, another week slides by without adverse comment and another top tier appointment. The only way way is up and my guess is that will happen Shortly (i.e. anytime between now and Christmas ;-)

Dear me, call me stupid but I actually respect and value both Ophidian and McNulty. I read what they say which is generally high value. I dont believe either would seek to deliverately mislead folk. Dosent mean I think that they have any obligation to do anything but it is a rare breed of bas***d who seeks to deliberately mislead and in my opinion Ophidian and McNulty are not that, in fact quite the reverse. Dosent mean I act on their opinions though, my cash my responsibility. I do think we have that rare breed on this board but not the aforementioned I think.

Seems likely to me that a numbef of LFTs will fail Sensitivity Checks so Abacta is actually likely to be well positioned with its second generation offering assuming they do resolve the cost of goods issue. Onward and upward.

Cheaper perhaps but definately inferior, also export to China may have been a factor with their penchant for ignoring IP.

Aptamer ...

I recollect Deepverge adopted Aptimers in the end, I guessed something to do with export to China.

"Decent rise" is it a spoof though, one of the 1.4 Billion or so having a laugh?

Erm, Sujood appears and it drops back 10 percent!

Got to feel for those ponies though.

On the plus side every Friday review that slides by without adverse comment confirms to me what I already feel in my bones, to wit its working.

Altruistic...

Seems to me that there is a certain sensitivity required when engaging with terminal phase patients. They are playing an altruism role in trying to benefit future cancer patients and AS getting excited about trial success half way through wouldnt seem to me to be all that considerate to them. When the trial completes is soon enough for me.

Not sure why you are concerned with not activating given that this is perhaps the most basic aspect other than so toxic it kills the recipient. Activation is a given in my opinion, how much activates outside the TME is however, an unknown but seems likely to align with or be better than the animal study given that mice apparently have more FAP in the blood than humans.

MTD to be determined in 1a and dosing regime in 1b. Could both look very different to current dox arrangements. All animals were alive at the end of the animal trial and AS declared that as though it was quite unusual is my opinion.

Chat for chats sake in my opinion. Clearly worked in mice and other animal models, clearly US convinced by the initial data. One hell of a lot of preliminary work undertaken to eliminate the basics such as toxicity and cleavage. For me its all about how much FAP in the blood to reduce the x 18 in the tumour, Id like to see a minimum of x 10, just has the right ring to it though if I was suffering with Cancer I think Id be quite keen on as little as x 2.

Must keep in mind that it was not only therapeutics that benefited from the Covid boost but AffiDX as well. Beyond the sars- cov -2 lft there will be a pipeline of other tests and that alone should make for decent returns.

Knowing what we know about the character of AS do you think he would drop a potentially best in world product and admit Avacta was essentiall defeated. Im betting not.

Also said getting cost of goods right and I hope they are addressing recycling issues. I hope for the final form for AffiDX, if they have any brains thats what they will be seeking to deliver.